Boston Scientific settles DoJ stent recall probe for $74m
This article was originally published in Clinica
Boston Scientific has agreed to pay $74m to settle a criminal investigation by the US Department of Justice into its voluntary recall in 1998 of a now obsolete stent system. The company has not admitted wrongdoing and no charges have been brought against it or any of its employees.
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.